{"id":321233,"date":"2026-10-21T16:18:44","date_gmt":"2026-10-21T10:48:44","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=321233"},"modified":"2026-10-21T16:18:44","modified_gmt":"2026-10-21T10:48:44","slug":"formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\/","title":{"rendered":"3 Formulations and APIs, Chronic Therapy Brands and Fermentation Ingredients Stocks With a Strong Future Roadmap: Ipca Laboratories, Eris Lifesciences and Concord Biotech"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Ipca Laboratories, Eris Lifesciences and Concord Biotech: ROE of 12.9% to 15.9% and FY22 to FY26 revenue CAGR of 10.7% to 22.9%. Prices as of 20 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three mid-cap pharma growth stocks to watch are Ipca Laboratories, Eris Lifesciences and Concord Biotech. Their return on equity ranges from 12.9% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.7% to 22.9%. Eris Lifesciences leads on both return on equity at 15.9% and revenue growth at 22.9% a year. Prices are based on the 20 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Mid-cap pharma growth stocks give investors access to companies that are scaling brands and ingredients without the size of the sector leaders. Ipca Laboratories, Eris Lifesciences and Concord Biotech combine formulations, chronic therapy brands and fermentation-based ingredients.<\/p>\n<p>This list covers three mid-cap pharma growth stocks with complete current figures: Ipca Laboratories, Eris Lifesciences and Concord Biotech. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\/#What_Are_Mid-cap_Pharma_Growth_Stocks\" title=\"What Are Mid-cap Pharma Growth Stocks?\">What Are Mid-cap Pharma Growth Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\/#Mid-cap_Pharma_Growth_Stocks_at_a_Glance\" title=\"Mid-cap Pharma Growth Stocks at a Glance\">Mid-cap Pharma Growth Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\/#Why_Do_Mid-cap_Pharma_Growth_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Mid-cap Pharma Growth Stocks Have a Strong Roadmap in India?\">Why Do Mid-cap Pharma Growth Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\/#Why_Ipca_Laboratories_Features_Among_These_Mid-cap_Pharma_Growth_Stocks\" title=\"Why Ipca Laboratories Features Among These Mid-cap Pharma Growth Stocks\">Why Ipca Laboratories Features Among These Mid-cap Pharma Growth Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\/#Why_Eris_Lifesciences_Features_Among_These_Mid-cap_Pharma_Growth_Stocks\" title=\"Why Eris Lifesciences Features Among These Mid-cap Pharma Growth Stocks\">Why Eris Lifesciences Features Among These Mid-cap Pharma Growth Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\/#Why_Concord_Biotech_Features_Among_These_Mid-cap_Pharma_Growth_Stocks\" title=\"Why Concord Biotech Features Among These Mid-cap Pharma Growth Stocks\">Why Concord Biotech Features Among These Mid-cap Pharma Growth Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\/#Ipca_Laboratories_vs_Eris_Lifesciences_vs_Concord_Biotech_on_Key_Financials\" title=\"Ipca Laboratories vs Eris Lifesciences vs Concord Biotech on Key Financials\">Ipca Laboratories vs Eris Lifesciences vs Concord Biotech on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\/#Key_Risks_to_Check_Before_Investing_in_Mid-cap_Pharma_Growth_Stocks\" title=\"Key Risks to Check Before Investing in Mid-cap Pharma Growth Stocks\">Key Risks to Check Before Investing in Mid-cap Pharma Growth Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\/#Final_Thoughts_on_Mid-cap_Pharma_Growth_Stocks\" title=\"Final Thoughts on Mid-cap Pharma Growth Stocks\">Final Thoughts on Mid-cap Pharma Growth Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\/#What_are_mid-cap_pharma_growth_stocks\" title=\"What are mid-cap pharma growth stocks?\">What are mid-cap pharma growth stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\/#Which_mid-cap_pharma_growth_stocks_are_covered_in_this_list\" title=\"Which mid-cap pharma growth stocks are covered in this list?\">Which mid-cap pharma growth stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\/#Why_do_mid-cap_pharma_growth_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do mid-cap pharma growth stocks have a strong future roadmap in India?\">Why do mid-cap pharma growth stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\/#How_has_Ipca_Laboratories_performed_financially\" title=\"How has Ipca Laboratories performed financially?\">How has Ipca Laboratories performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\/#How_has_Eris_Lifesciences_performed_financially\" title=\"How has Eris Lifesciences performed financially?\">How has Eris Lifesciences performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\/#How_has_Concord_Biotech_performed_financially\" title=\"How has Concord Biotech performed financially?\">How has Concord Biotech performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\/#What_risks_should_investors_check_before_buying_mid-cap_pharma_growth_stocks\" title=\"What risks should investors check before buying mid-cap pharma growth stocks?\">What risks should investors check before buying mid-cap pharma growth stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients-stocks-roadmap-trailhead-list\/#Is_this_list_of_mid-cap_pharma_growth_stocks_investment_advice\" title=\"Is this list of mid-cap pharma growth stocks investment advice?\">Is this list of mid-cap pharma growth stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Mid-cap_Pharma_Growth_Stocks\"><\/span><strong>What Are Mid-cap Pharma Growth Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Mid-cap pharma growth stocks are mid-sized listed pharmaceutical companies that sell branded formulations, active ingredients or both. Their earnings depend on prescription growth, product launches and the use of their manufacturing capacity.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Mid-cap_Pharma_Growth_Stocks_at_a_Glance\"><\/span><strong>Mid-cap Pharma Growth Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/ipcalab\/ipca-laboratories-ltd-share-price-today\">Ipca Laboratories<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,814.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">46,050<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.10<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/eris\/eris-lifesciences-ltd-share-price-today\">Eris Lifesciences<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,120.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15,618<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.60<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/concordbio\/concord-biotech-ltd-share-price-today\">Concord Biotech<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,285.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13,421<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">49.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.00<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Ipca Laboratories and Eris Lifesciences trade at a P\/E below the industry P\/E, while Concord Biotech trades above it, which reflects the growth the market already expects. Readers comparing mid-cap pharma growth stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Mid-cap_Pharma_Growth_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Mid-cap Pharma Growth Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Mid-cap pharma growth stocks have a strong roadmap in India because mid-sized companies can grow faster from a smaller base while chronic therapy demand and ingredient exports keep rising.<\/p>\n<ul>\n<li><strong>Chronic therapy growth.<\/strong> Cardiac, diabetes and gastro-intestinal care need long-term treatment.<\/li>\n<li><strong>Ingredient demand.<\/strong> Fermentation-based products serve transplant, anti-infective and other global needs.<\/li>\n<li><strong>Scale benefits.<\/strong> Higher volumes on existing plants can lift margins.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Ipca_Laboratories_Features_Among_These_Mid-cap_Pharma_Growth_Stocks\"><\/span><strong>Why Ipca Laboratories Features Among These Mid-cap Pharma Growth Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the mid-cap pharma growth stocks on this list, Ipca Laboratories is a Mumbai-based pharmaceutical company that makes formulations and active ingredients, with leading brands in pain management, anti-malarials, cardiovascular and anti-infective therapies.<\/p>\n<p>Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%.<\/p>\n<p>In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P\/E of 33.5, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.<\/p>\n<p><strong>What to watch:<\/strong> Monitor the growth of the branded domestic business and the capacity utilisation of its active ingredient plants.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Eris_Lifesciences_Features_Among_These_Mid-cap_Pharma_Growth_Stocks\"><\/span><strong>Why Eris Lifesciences Features Among These Mid-cap Pharma Growth Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the fermentation-based pharma shares on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.<\/p>\n<p>In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%.<\/p>\n<p>Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P\/E of 23.5, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.<\/p>\n<p><strong>What to watch:<\/strong> Check how smoothly acquired brands are integrated and how the injectables unit scales.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Concord_Biotech_Features_Among_These_Mid-cap_Pharma_Growth_Stocks\"><\/span><strong>Why Concord Biotech Features Among These Mid-cap Pharma Growth Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Concord Biotech is a Gujarat-based biopharma company that makes fermentation-based active ingredients such as immunosuppressants, oncology drugs and anti-infectives for global pharma customers.<\/p>\n<p>The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P\/E of 49.2, above the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.<\/p>\n<p><strong>What to watch:<\/strong> Monitor the pace of new product introductions and the contribution from formulations.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Ipca_Laboratories_vs_Eris_Lifesciences_vs_Concord_Biotech_on_Key_Financials\"><\/span><strong>Ipca Laboratories vs Eris Lifesciences vs Concord Biotech on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three mid-cap pharma growth stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Ipca Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,896<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,821<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.6%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,191<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Eris Lifesciences<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,373<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,137<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22.9%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">648<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Concord Biotech<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">736<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,107<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.7%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">259<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.4%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Eris Lifesciences posts the highest return on equity in this group at 15.9%. Ipca Laboratories has the largest FY26 revenue at Rs 9,821 crore, and Eris Lifesciences shows the fastest revenue growth with a 22.9% compound annual rate. A useful habit with mid-cap pharma growth stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Ipca Laboratories<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,342<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,813<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20.2%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Eris Lifesciences<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">776<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">876<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.9%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Concord Biotech<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">218<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">270<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">24.2%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Mid-cap_Pharma_Growth_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Mid-cap Pharma Growth Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these mid-cap pharma growth stocks, the main points are: Long-term fermentation-based pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Scale limits.<\/strong> Mid-sized companies have a thinner cushion if a key product slows.<\/li>\n<li><strong>Regulatory approvals.<\/strong> Delays in plant or product approvals can push out launches.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter mid-cap pharma growth stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Mid-cap_Pharma_Growth_Stocks\"><\/span><strong>Final Thoughts on Mid-cap Pharma Growth Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Mid-cap pharma growth stocks reward investors who study brand growth, plant utilisation and approvals closely. Ipca Laboratories, Eris Lifesciences and Concord Biotech each have levers to keep growing. Based on the 20 October 2026 close, Ipca Laboratories trades at Rs 1,814.5, Eris Lifesciences at Rs 1,120.4 and Concord Biotech at Rs 1,285.8. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these mid-cap pharma growth stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track mid-cap pharma growth stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_mid-cap_pharma_growth_stocks\"><\/span><strong>What are mid-cap pharma growth stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Mid-cap pharma growth stocks are mid-sized listed pharmaceutical companies that sell branded formulations, active ingredients or both. Their earnings depend on prescription growth, product launches and the use of their manufacturing capacity. This list looks at three of them, Ipca Laboratories, Eris Lifesciences and Concord Biotech, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_mid-cap_pharma_growth_stocks_are_covered_in_this_list\"><\/span><strong>Which mid-cap pharma growth stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Ipca Laboratories, Eris Lifesciences and Concord Biotech. Based on the 20 October 2026 close, Ipca Laboratories traded at Rs 1,814.5, Eris Lifesciences at Rs 1,120.4 and Concord Biotech at Rs 1,285.8. Their return on equity ranges from 12.9% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.7% to 22.9%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_mid-cap_pharma_growth_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do mid-cap pharma growth stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Mid-cap pharma growth stocks have a strong roadmap in India because mid-sized companies can grow faster from a smaller base while chronic therapy demand and ingredient exports keep rising. The main drivers are as follows. Chronic therapy growth. Cardiac, diabetes and gastro-intestinal care need long-term treatment. Ingredient demand. Fermentation-based products serve transplant, anti-infective and other global needs. Scale benefits. Higher volumes on existing plants can lift margins. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Ipca_Laboratories_performed_financially\"><\/span><strong>How has Ipca Laboratories performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P\/E of 33.5, below the industry P\/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Eris_Lifesciences_performed_financially\"><\/span><strong>How has Eris Lifesciences performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P\/E of 23.5, below the industry P\/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Concord_Biotech_performed_financially\"><\/span><strong>How has Concord Biotech performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P\/E of 49.2, above the industry P\/E of 36.0. Looking ahead, the company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_mid-cap_pharma_growth_stocks\"><\/span><strong>What risks should investors check before buying mid-cap pharma growth stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying mid-cap pharma growth stocks. Scale limits. Mid-sized companies have a thinner cushion if a key product slows. Regulatory approvals. Delays in plant or product approvals can push out launches. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_mid-cap_pharma_growth_stocks_investment_advice\"><\/span><strong>Is this list of mid-cap pharma growth stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are mid-cap pharma growth stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Mid-cap pharma growth stocks are mid-sized listed pharmaceutical companies that sell branded formulations, active ingredients or both. Their earnings depend on prescription growth, product launches and the use of their manufacturing capacity. This list looks at three of them, Ipca Laboratories, Eris Lifesciences and Concord Biotech, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which mid-cap pharma growth stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Ipca Laboratories, Eris Lifesciences and Concord Biotech. Based on the 20 October 2026 close, Ipca Laboratories traded at Rs 1,814.5, Eris Lifesciences at Rs 1,120.4 and Concord Biotech at Rs 1,285.8. Their return on equity ranges from 12.9% to 15.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.7% to 22.9%.\"}},{\"@type\":\"Question\",\"name\":\"Why do mid-cap pharma growth stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Mid-cap pharma growth stocks have a strong roadmap in India because mid-sized companies can grow faster from a smaller base while chronic therapy demand and ingredient exports keep rising. The main drivers are as follows. Chronic therapy growth. Cardiac, diabetes and gastro-intestinal care need long-term treatment. Ingredient demand. Fermentation-based products serve transplant, anti-infective and other global needs. Scale benefits. Higher volumes on existing plants can lift margins. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Ipca Laboratories performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P\/E of 33.5, below the industry P\/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.\"}},{\"@type\":\"Question\",\"name\":\"How has Eris Lifesciences performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P\/E of 23.5, below the industry P\/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.\"}},{\"@type\":\"Question\",\"name\":\"How has Concord Biotech performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P\/E of 49.2, above the industry P\/E of 36.0. Looking ahead, the company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying mid-cap pharma growth stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying mid-cap pharma growth stocks. Scale limits. Mid-sized companies have a thinner cushion if a key product slows. Regulatory approvals. Delays in plant or product approvals can push out launches. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of mid-cap pharma growth stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mid-cap Pharma Growth Stocks with a strong future roadmap: Ipca Laboratories, Eris Lifesciences and Concord Biotech. Compare price, valuation, return on equity and revenue growth as of 20 October 2026.<\/p>\n","protected":false},"author":34,"featured_media":321232,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,14182,11240,13903,14181,13964,14180],"class_list":["post-321233","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-branded-formulation-stocks","tag-concord-biotech","tag-eris-lifesciences","tag-fermentation-based-pharma-shares","tag-ipca-laboratories","tag-mid-cap-pharma-growth-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["321232"],"rank_math_title":["Mid-Cap Pharma Growth Stocks With a Clear Roadmap"],"rank_math_description":["Compare 3 mid-cap pharma growth stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 20 Oct 2026."],"rank_math_focus_keyword":["mid-cap pharma growth stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-formulations-and-apis-chronic-therapy-brands-and-fermentation-ingredients.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/321233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=321233"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/321233\/revisions"}],"predecessor-version":[{"id":321234,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/321233\/revisions\/321234"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/321232"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=321233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=321233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=321233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}